Enhancing Molecular Diagnostic Accuracy in Genetic Eye Disorders Through a Personalized Re-Evaluation Strategy
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.1.62 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Pedro Moreira Martins and 6 co-authors. Institution: Department of Ophthalmology, Unidade Local de Saúde de Gaia e Espinho, Gaia, Porto, Portugal. Major MEDLINE topics: Genetic Testing, Molecular Diagnostic Techniques, Eye Diseases, Hereditary, Precision Medicine. Cited 1 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Although genetic testing is crucial to provide prognostic information in genetic eye disorders (GEDs), up to 35% of cases remain unsolved after testing. We aim to describe how a tailored re-evaluation strategy, using up-to-date molecular testing, case-by-case review, and integration of in silico tools may increase the diagnostic yield.
Methods
A total of 988 individuals from 800 families evaluated at the largest Portuguese GED referral center (Hospitais da Universidade de Coimbra) were included. All had a clinical diagnosis based on clinical findings and deep phenotyping and underwent genetic testing. Targeted re-evaluation included updated Next Generation Sequencing (NGS) panels, Exome Sequencing (ES) reanalysis, and assays for intronic variants, copy number variants, and ORF15-RPGR region. Variants of uncertain significance (VUS) were reassessed using segregation studies, literature/database review, and bioinformatic tools.
Results
Initial testing yielded a molecular diagnosis in 475 families (59.4%). Variant reclassification enabled 39 additional diagnoses. A personalized re-testing strategy resolved 43 more, either through updated NGS panels (11), ES-reanalysis (14) and identification of deletions, GC-rich, and intronic variants (22). Overall, the solved rate increased from 59.4% to 70.1%. An additional 45 families (5.6%) carry phenotype-consistent VUS that could not be reclassified at the present date (partially-solved cases).
Conclusions
This personalized re-evaluation strategy, incorporating state-of-the-art genetic testing, evidence-based variant reclassification, and case review by a multidisciplinary team increased the solved rate by over 10%. Consequently, 86 additional families received a definitive diagnosis and accurate genetic counseling, underscoring the impact of periodic re-evaluation and continuous improvement in genetic testing methodologies.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Ophthalmology, Unidade Local de Saúde de Gaia e Espinho, Gaia, Porto, Portugal.
- Department of Ophthalmology, Hospitais da Universidade de Coimbra (HUC), Unidade Local de Saúde de Coimbra (ULS-C), Coimbra, Portugal.
- Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.
- Medical Genetics Department, Hospital Pediátrico de Coimbra (HPC), Unidade Local de Saúde de Coimbra (ULS-C), Coimbra, Portugal.
Cite
APA
Martins, P. M., Figueiredo, I., Cruz, N., Gaspar, B. R., Silva, R., Carvalho, A. L., & Marques, J. P. (2026). Enhancing Molecular Diagnostic Accuracy in Genetic Eye Disorders Through a Personalized Re-Evaluation Strategy. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.62
Vancouver
Martins PM, Figueiredo I, Cruz N, Gaspar BR, Silva R, Carvalho AL, et al. Enhancing Molecular Diagnostic Accuracy in Genetic Eye Disorders Through a Personalized Re-Evaluation Strategy. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.62
BibTeX
@article{Martins2026,
author = {Martins, Pedro Moreira and Figueiredo, Inês and Cruz, Nuno and Gaspar, Beatriz Rodrigues and Silva, Rufino and Carvalho, Ana Luísa and Marques, João Pedro},
title = {Enhancing Molecular Diagnostic Accuracy in Genetic Eye Disorders Through a Personalized Re-Evaluation Strategy},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.1.62}
}
EUVIMED